Cardiovascular Disease Risk Reduction and Body Mass Index

被引：13

作者：

Samson, Rohan ^{[1
]}

Ennezat, Pierre Vladimir ^{[2
]}

Le Jemtel, Thierry H. ^{[1
]}

Oparil, Suzanne ^{[3
]}

机构：

[1] Tulane Univ, Sch Med, John W Deming Dept Med, Sect Cardiol, 1430 Tulane Ave, New Orleans, LA 70112 USA

[2] Hop Univ Henri Mondor, AP HP, Dept Cardiol, Creteil, France

[3] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA

来源：

CURRENT HYPERTENSION REPORTS | 2022年 / 24卷 / 11期

关键词：

Obesity; Hypertension; Body mass index; Cardiovascular disease; VISCERAL ADIPOSITY INDEX; LEFT-VENTRICULAR MASS; CORONARY-HEART-DISEASE; BLOOD-PRESSURE; CARDIOMETABOLIC RISK; INSULIN SENSITIVITY; METABOLIC SYNDROME; DIABETES-MELLITUS; OBESITY FINDINGS; ADULT OBESITY;

D O I：

10.1007/s11906-022-01213-5

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Purpose of Review Anti-hypertensive and lipid lowering therapy addresses only half of the cardiovascular disease risk in patients with body mass index > 30 kg/m(2), i.e., obesity. We examine newer aspects of obesity pathobiology that underlie the partial effectiveness of anti-hypertensive lipid lowering therapy for the reduction of cardiovascular disease risk in obesity. Recent Findings Obesity-related insulin resistance, vascular endothelium dysfunction, increased sympathetic nervous system/renin-angiotensin-aldosterone system activity, and glomerulopathy lead to type 2 diabetes, coronary atherosclerosis, and chronic disease kidney disease that besides hypertension and dyslipidemia increase cardiovascular disease risk. Obesity increases cardiovascular disease risk through multiple pathways. Optimal reduction of cardiovascular disease risk in patients with obesity is likely to require therapy targeted at both obesity and obesity-associated conditions.

引用

页码：535 / 546

页数：12

共 165 条

[1] Left Ventricular Mass and Incident Chronic Kidney Disease [J].